Key Takeaways:
- Kenvue reported Q1 2026 net sales growth of 4.5% to $3.91 billion, with adjusted EPS of $0.32, beating analyst estimates and diluted EPS rising 47% to $0.25.
- KVUE stock trades near $17, with a 52-week range of $14 to $24, a street analyst target of around $19, and a pending acquisition by Kimberly-Clark adding a major strategic variable.
- KVUE stock could rise from $18 to around $22 per share by December 2028, based on 3% annual revenue growth, 22.6% operating margins, and a 14.5x P/E multiple.
- That implies a total return of around 23% and an annualized return of about 8.3% per year over the next 2.6 years.
What Happened?
Kenvue (KVUE) delivered solid first-quarter results for 2026 despite an ongoing business transition. Net sales grew 4.5% to $3.91 billion, and diluted EPS rose 47% to $0.25. Adjusted EPS came in at $0.32, beating analyst estimates. Investors noted the results positively, though the pending Kimberly-Clark acquisition continues to dominate the broader narrative around the stock.
The Kimberly-Clark acquisition is the most significant strategic overhang for Kenvue shareholders. Reuters valued the deal at around $40 billion, and it would combine Kenvue’s consumer health brands with Kimberly-Clark’s personal care products portfolio.
Kimberly-Clark retained Carlos Urdaneta as CFO of the combined company, while Kenvue named Heather Howlett as interim CFO effective May 12. These leadership moves signal active integration planning and an accelerating deal timeline.
Kenvue is also managing internal restructuring alongside the acquisition process. The company initiated a workforce reduction of around 3.5% as part of an efficiency program announced in February 2026.
An SEC filing cited expected continued variability in its operating environment due to the Middle East conflict. Both disclosures highlight the dual complexity of managing restructuring and integration planning simultaneously.
The company maintained its quarterly dividend of $0.2075 per share, supporting a yield of around 4.9%. Shareholders elected 12 directors at the May 2026 annual meeting without major governance surprises. Kenvue also collaborated with Greyparrot to advance AI-powered circular packaging efforts, reflecting ongoing sustainability commitments.
Here’s why Kenvue stock could offer solid capital returns through 2028 as its core business drivers support shareholder value.
What the Model Says for KVUE Stock
We analyzed the upside potential for Kenvue stock based on its consumer health brand portfolio, pricing power in self-care categories, and the potential impact of the Kimberly-Clark acquisition process on business performance.
Based on estimates of 3% annual revenue growth, 22.6% operating margins, and a normalized P/E multiple of 14.5x, the model projects Kenvue stock could rise from $18 to around $22 per share.
That would be a 23% total return, or an 8.3% annualized return over the next 2.6 years.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for KVUE stock:
1. Revenue Growth: 3%
Kenvue reported a 1-year revenue decline of around 2.1% but returned to positive growth in Q1 2026, with net sales up 4.5%. The company’s portfolio spans self-care, skin health, and essential health products across multiple well-known consumer brands in over 150 countries.
Near-term revenue growth faces headwinds from macroeconomic uncertainty and the Middle East conflict, as disclosed in Kenvue’s SEC filing. The pending Kimberly-Clark deal also introduces uncertainty around product focus and geographic priorities following the close.
Based on analysts’ consensus estimates, we used 3% annual revenue growth, reflecting a modest but realistic recovery from recent declines. This is above the recent 1-year rate and aligns with analyst expectations for steady brand-led growth in consumer health categories through 2028.
2. Operating Margins: 22.6%
Kenvue reported an LTM EBIT margin of 19.7% and a gross margin of 58.6%, reflecting the strength of its branded product portfolio. The forward model uses 22.6% operating margins, reflecting expected improvement from the workforce reduction and operational streamlining.
The 3.5% workforce reduction should generate cost savings over the medium term. However, restructuring charges may suppress reported margins in the near term, creating some timing risk on the expansion path.
Based on analysts’ consensus estimates, we used 22.6% operating margins, reflecting modest improvement from current reported levels. A successful efficiency program or accelerated Kimberly-Clark integration could push margins above the base case over time.
3. Exit P/E Multiple: 14.5x
Kenvue trades at an NTM P/E of around 14.5x, which is at the lower end of historical ranges for large consumer health companies. The stock’s 1-year decline of around 22% has significantly compressed the multiple from prior peak levels near $24.
Street analyst consensus places a target of around $19, implying limited upside of around 10% on a standalone basis. A dividend yield of 4.9% partially offsets this through income, providing support to total returns for patient shareholders.
Based on analysts’ consensus estimates, we used a 14.5x exit P/E multiple, consistent with current market pricing and the company’s branded consumer health model. The Kimberly-Clark acquisition introduces additional deal uncertainty, but could ultimately result in a premium to the standalone valuation.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Different scenarios for KVUE stock through 2034 show varied outcomes based on revenue recovery, margin improvement, and acquisition outcome (these are estimates, not guaranteed returns):
- Low Case: Revenue growth stays limited near 2.5%, and margin expansion disappoints → 4.8% annual returns
- Mid Case: Steady brand-led growth of 2.8% and improving margins support solid income and capital return → 7.1% annual returns
- High Case: Stronger revenue recovery of 3.1% and full margin expansion drive outsized total returns → 9.0% annual returns
Going forward, Kenvue stock offers a conservative but potentially interesting return profile for income-oriented investors. The near-term guided model projects around 8.3% annualized returns through 2028, just below the 10% attractive threshold, but the 4.9% dividend yield meaningfully adds to total return potential.
Investors should closely monitor the Kimberly-Clark acquisition timeline and deal terms, as these developments will likely define how the stock trades over the next 12 to 24 months.
See what analysts think about KVUE stock right now (Free with TIKR) >>>
Should You Invest in Kenvue?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up KVUE, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track KVUE alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze the stock on TIKR Free→
Looking for New Opportunities?
- See what stock billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
